Search clinical trials for: rituximab [MabThera]

Total 3112 results

JHL Biotech, Inc.

Terminated

A Study of JHL1101 Versus MabThera® in Subjects With Severe Rheumatoid Arthritis

Arthritis, Rheumatoid | Rheumatoid Arthritis

Bosnia and Herzegovina, Bulgaria, Czechia, Germany, Hungary, Lithuania, Poland, Russian Federation, Taiwan, Ukraine, United Kingdom
Nantes University Hospital
Hoffmann-La Roche; French Innovative Leukemia Organisation

Completed

High-dose Chemotherapy With Rituximab for Adults With Aggressive Large B-cell Lymphoma

B-Cell Lymphoma

France
SecuraBio

Terminated

Study of Duvelisib in Combination With Rituximab vs Rituximab in Subjects With Previously Treated Follicular Lymphoma (DYNAMO + R)

Follicular Lymphoma

France, Italy, Australia, Poland
Newcastle-upon-Tyne Hospitals NHS Trust
Newcastle University; National Institute for Health Research, United Kingdom; Department of Health, United Kingdom

Completed

B-Cell Depleting Therapy (Rituximab) as a Treatment for Fatigue in Primary Biliary Cirrhosis (RITPBC)

Fatigue | Primary Biliary Cirrhosis

United Kingdom
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Active, not recruiting

Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Grade 3a Follicular... and other conditions

United States
Hoffmann-La Roche
Biogen

Completed

A Study of the Efficacy and Safety of Re-treatments With Rituximab in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-tnfa Therapies

Rheumatoid Arthritis

Belgium, Germany, Norway, United Kingdom, United States, Ireland, France, Canada, Israel, Netherlands, Italy
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Zanubrutinib and Rituximab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

United States
Medical University of Vienna

Recruiting

Efficacy of Polatuzumab, Bendamustine and Rituximab in Patients With Relapsed/ Refractory Mantle Cell Lymphoma

Mantle-cell Lymphoma

Austria
Centre Hospitalier Universitaire de Saint Etienne
Ministry of Health, France

Recruiting

Rituximab Therapy in Anti-Myelin Associated Glycoprotein Patients With Characteristics of Good Responders (THERAMAG)

Anti-MAG Neuropathy

France
Hoffmann-La Roche
Nordic Lymphoma Group

Completed

A Study of MabThera/Rituxan (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma

Lymphoma

Sweden, Denmark, Norway
Hoffmann-La Roche

Completed

A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a TNF-Blocker.

Rheumatoid Arthritis

Hungary
Dana-Farber Cancer Institute
HiberCell, Inc.

Completed

A Phase 2 Clinical Trial of Rituxan and B-Glucan PGG in Relapsed Indolent Non-Hodgkin Lymphoma

Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphomas

United States
Fudan University

Terminated

Dose-adjusted EPOCH-R in MYC Positive DLBCL

Diffuse Large B-cell Lymphoma

China
Hoffmann-La Roche

Completed

A Study to Compare Subcutaneous Versus Intravenous MabThera (Rituximab) in Combination With Chemotherapy in Patients With Chronic Lymphocytic Leukemia

Lymphocytic Leukemia, Chronic

Australia, Brazil, Spain, Italy, Canada, Germany, Chile, Mexico, France, Argentina, Croatia, Russian Federation, Slovakia, Turkey, Poland, Czechia, New Zealand, Portugal, Greece
Hoffmann-La Roche

Completed

A Study of MabThera Added to Bendamustine or Chlorambucil in Patients With Chronic Lymphocytic Leukemia (MaBLe)

Lymphocytic Leukemia, Chronic

Finland, France, Spain, Portugal, Turkey, United Kingdom, Sweden, Tunisia
Chinese University of Hong Kong

Completed

An Analysis of Peripheral Blood T Cell Subsets on Rheumatoid Arthritis

Rheumatoid Arthritis

China
Fredrik Piehl

Unknown

A Study Evaluating the Safety and Efficacy of Rituximab in Patients With Myasthenia Gravis (Rinomax)

Generalized Myasthenia Gravis

Sweden
Ranjana Advani
Genentech, Inc.

Completed

Rituximab in Treating Patients With Hodgkin's Lymphoma

Lymphoma | Hodgkin Lymphoma (Category) | Nodular Lymphocyte Predominant Hodgkin Lymphoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma

Recurrent Mantle Cell Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Refractory Mantle Cell Lymphoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Ibrutinib With or Without Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia

Recurrent Small Lymphocytic Lymphoma | Prolymphocytic Leukemia | Recurrent Chronic Lymphocytic Leukemia

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Lenalidomide in Combination With Rituximab in Treating Participants With Stage III/IV Indolent Non-Hodgkin Lymphoma

Ann Arbor Stage III Grade 1 Follicular Lymphoma | Ann Arbor Stage III Grade 2 Follicular Lymphoma | Ann Arbor Stage III Indolent Adult Non-Hodgkin Lymphoma | Ann Arbor Stage IV Grade 1 Follicular Lymphoma | Ann Arbor Stage IV Grade 2 Follicular Lymphoma | Ann Arbor Stage IV Indolent Adult Non-Hodgkin... and other conditions

United States
MEI Pharma, Inc.
Kyowa Kirin, Inc.

Withdrawn

Rituximab Plus Venetoclax in Combination With Zandelisib in Subjects With CLL (CORAL)

CLL

United States
Novartis Pharmaceuticals
GlaxoSmithKline

Terminated

Single Agent Ofatumumab Vs. Single Agent Rituximab in Indolent B-Cell Non Hodgkin Lymphoma Relapsed After Rituximab-Containing Therapy (HOMER)

Non-Hodgkin's Lymphoma

China, United States, Belgium, Czechia, France, Japan, Bulgaria, Canada, Hungary, Peru, Slovakia, South Africa, Ukraine, Korea, Republic of, Puerto Rico, Brazil
M.D. Anderson Cancer Center

Recruiting

ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma

Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Richter Syndrome | Refractory Mantle Cell Lymphoma | Refractory Aggressive B-Cell Non-Hodgkin Lymphoma | Refractory High Grade B-Cell Lymphoma | Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma | Refractory... and other conditions

United States
Copenhagen University Hospital at Herlev

Completed

Prednisolone +/- Addition of Anti-CD20 Antibody, Rituximab, in Patients With Immune Hemolytic Anemia

Anemia, Hemolytic, Autoimmune

Denmark
M.D. Anderson Cancer Center

Active, not recruiting

Acalabrutinib and Rituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma

Mantle Cell Lymphoma

United States
Grupo Español de Linfomas y Transplante Autólogo...

Completed

Transplantation With Ybritumomab Tiuxetan (Zevalin) Plus BEAM Regimen in Patients With Refractory Large B-cell Difusse Lymphom (Z-BEAM LDGGB)

Non-Hodgkin's Lymphoma

Spain
German Low Grade Lymphoma Study Group

Terminated

Study With Rituximab-Gemcitabine/Oxaliplatin in Relapsed Indolent Lymphoma (R-GO)

Indolent Lymphoma

Germany
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell Lymphoma

Recurrent Mantle Cell Lymphoma | Mantle Cell Lymphoma | CCND1 Positive | CCND2 Positive | CCND3 Positive | CD20 Positive | Refractory Mantle Cell Lymphoma

United States
Assistance Publique - Hôpitaux de Paris
French Vasculitis Study Group

Completed

Rituximab in Eosinophilic Granulomatosis With Polyangiitis (REOVAS)

Eosinophilic Granulomatosis With Polyangiitis (EGPA)

France
National Cancer Institute (NCI)

Terminated

Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma

Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Lymphoblastic Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone... and other conditions

United States
Asociacion Espanola de Hematologia y Hemoterapia

Completed

Efficacy Response Duration and Toxicity of Rituximab, Fludarabine, and Cyclophosphamide (RFC) as 1st Line Treatment and Rituximab (R) in Maintenance Treatment in Follicular Non Hodgkin (FNH) Lymphoma

Non Hodgkin Lymphoma

Spain
National Cancer Institute (NCI)
Celgene Corporation

Active, not recruiting

Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma

Ann Arbor Stage III Grade 1 Follicular Lymphoma | Ann Arbor Stage III Grade 2 Follicular Lymphoma | Ann Arbor Stage IV Grade 1 Follicular Lymphoma | Ann Arbor Stage IV Grade 2 Follicular Lymphoma | Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma | Ann Arbor Stage II Grade 3 Non-Contiguous... and other conditions

United States
Ohio State University Comprehensive Cancer Center
Millennium Pharmaceuticals, Inc.

Terminated

Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade... and other conditions

United States
Hoffmann-La Roche

Completed

CHAIROS Study A Study of MabThera/Rituxan (Rituximab) Maintenance Therapy in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Naive to Chemotherapy

Lymphocytic Leukemia, Chronic

Austria
Mabscale, LLC

Recruiting

Study, Evaluating Pharmacokinetics, Pharmacodynamics, Immunogenicity and Safety Profiles of Rituximab Compared to MabThera® in Patients With Rheumatoid Arthritis

Rheumatoid Arthritis

Russian Federation
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia

Hairy Cell Leukemia | Recurrent Hairy Cell Leukemia

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Rituximab With or Without Yttrium Y-90 Ibritumomab Tiuxetan in Treating Patients With Untreated Follicular Lymphoma

Ann Arbor Stage I Grade 1 Follicular Lymphoma | Ann Arbor Stage I Grade 2 Follicular Lymphoma | Ann Arbor Stage III Grade 1 Follicular Lymphoma | Ann Arbor Stage III Grade 2 Follicular Lymphoma | Ann Arbor Stage IV Grade 1 Follicular Lymphoma | Ann Arbor Stage IV Grade 2 Follicular Lymphoma | Ann... and other conditions

United States
Rutgers, The State University of New Jersey
National Cancer Institute (NCI)

Withdrawn

Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements | Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements | Recurrent Burkitt Lymphoma | Refractory Burkitt... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Rituximab and Pembrolizumab With or Without Lenalidomide in Treating Patients With Relapsed Follicular Lymphoma and Diffuse Large B-Cell Lymphoma

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Recurrent Grade 3a Follicular Lymphoma

United States
Institute of Hematology & Blood Diseases Hospital

Unknown

The Comparison of RCD Versus BCD in Newly Diagnosed Waldenström Macroglobulinemia (BDH-WM01)

Waldenström Macroglobulinemia

China
Hoffmann-La Roche
Genentech, Inc.; German CLL Study Group

Completed

CLL11: A Study of Rituximab With Chlorambucil or Chlorambucil Alone in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1b)

Lymphocytic Leukemia, Chronic

Australia, France, Germany, Italy, Spain, Hong Kong, Canada, Switzerland, Estonia, Mexico, New Zealand, Denmark, Russian Federation, United States, Austria, Bulgaria, Czechia, United Kingdom, Thailand, Romania, Croatia, Brazil, Arge... and more
Christian Buske
Hoffmann-La Roche; Johnson & Johnson; ClinAssess GmbH; University of Ulm; Zentrum...

Active, not recruiting

Efficacy of First Line B-RI for Treatment Naive Waldenström's Macroglobulinemia

Waldenstrom Macroglobulinemia

Germany, Greece
Kami Maddocks, MD
Novartis

Completed

Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone... and other conditions

United States
National Taiwan University Hospital

Terminated

De Novo Everolimus-based Therapy for Renal Transplantation Using Rituximab Induction

Renal Insufficiency

Taiwan
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Ixazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

Recurrent Mantle Cell Lymphoma | Refractory Mantle Cell Lymphoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Janssen, LP

Completed

Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone Lymphoma

CD20 Positive | Ann Arbor Stage II Follicular Lymphoma | Ann Arbor Stage III Follicular Lymphoma | Ann Arbor Stage IV Follicular Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular Lymphoma | Ann Arbor Stage II Marginal Zone Lymphoma | Ann Arbor Stage III Marginal... and other conditions

United States
University of Washington
Merck Sharp & Dohme LLC

Active, not recruiting

Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma

United States
Pfizer

Completed

A Pharmacokinetic/Pharmacodynamic Study Comparing PF-05280586 To Rituximab In Subjects With Active Rheumatoid Arthritis With An Inadequate Response To TNF Inhibitors (REFLECTIONS B328-01) (REFLECTIONS)

Rheumatoid Arthritis

United States, United Kingdom, Australia, Mexico, South Africa, Canada, Colombia, Germany, Israel, Russian Federation
Hoffmann-La Roche

Completed

A Study of Escalating Doses of DCDS0780A in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma

United States

Search clinical trials for: rituximab [MabThera]

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bosnia & Herzegovina

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations